United Therapeutics (UTHR) CEO sells 19,000 shares under Rule 10b5-1 trading plan

Rhea-AI Filing Summary

United Therapeutics Corp Chairperson and CEO Martine A. Rothblatt reported an insider transaction involving stock options and common shares. On March 4, 2026, she exercised 9,500 stock options (labeled as Stock Options) at a reported exercise price of $0.0000 per share, leaving her with 211,500 stock options held directly following the exercise.

The same day, she executed a series of open-market sales totaling 19,000 shares of Common Stock, with reported per‑share prices including $486.4229 and up to $497.0500. After these sales, she held 130 shares of Common Stock directly. Additional indirect Common Stock holdings are reported as 166 shares held by spouse and 324,518, 258,117, 45,596, and 10,962 shares held by various family trusts. A footnote states that the option exercise and related share sales were carried out under a pre‑arranged Rule 10b5‑1 trading plan adopted on November 7, 2025, which will continue until the earlier of the exercise of 1,734,410 stock options expiring on March 17, 2027 or December 31, 2026.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

ROTHBLATT MARTINE A

(Last) (First) (Middle)

C/O UNITED THERAPEUTICS CORPORATION

1000 SPRING STREET

(Street)

SILVER SPRING MD 20910

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
UNITED THERAPEUTICS Corp [ UTHR ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chairperson & CEO

3. Date of Earliest Transaction (Month/Day/Year)
03/04/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/04/2026		S(1)		9,500	A	$146.03	9,630	D
Common Stock	03/04/2026		S(1)		399	D	$486.4229(2)	9,231	D
Common Stock	03/04/2026		S(1)		926	D	$487.5539(3)	8,305	D
Common Stock	03/04/2026		S(1)		2,429	D	$488.6298(4)	5,876	D
Common Stock	03/04/2026		S(1)		2,290	D	$489.6797(5)	3,586	D
Common Stock	03/04/2026		S(1)		1,808	D	$490.5187(6)	1,778	D
Common Stock	03/04/2026		S(1)		485	D	$491.3325(7)	1,293	D
Common Stock	03/04/2026		S(1)		243	D	$492.4388(8)	1,050	D
Common Stock	03/04/2026		S(1)		185	D	$493.3979(9)	865	D
Common Stock	03/04/2026		S(1)		215	D	$494.7391(10)	650	D
Common Stock	03/04/2026		S(1)		480	D	$495.7842(11)	170	D
Common Stock	03/04/2026		S(1)		40	D	$497.05	130	D
Common Stock								166	I	by Spouse
Common Stock								324,518	I	by Trust(12)
Common Stock								258,117	I	by Trust(13)
Common Stock								45,596	I	by Trust(14)
Common Stock								10,962	I	by Trust(15)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Options	$146.03	03/04/2026		M(1)			9,500	03/15/2020	03/15/2027	Common Stock	9,500	$0.00	211,500	D

Explanation of Responses:

1. This exercise of stock options and sale of the resulting shares of common stock was pursuant to a pre-arranged 10b5-1 trading plan adopted by the reporting person on November 7, 2025. This plan will continue until the earlier of: (a) the exercise of 1,734,410 stock options, all of which expire on March 17, 2027; or (b) December 31, 2026.

2. This transaction was executed in multiple trades at prices ranging from $486.01 to $486.90. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

3. This transaction was executed in multiple trades at prices ranging from $487.05 to $488.03. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

4. This transaction was executed in multiple trades at prices ranging from $488.07 to $489.04. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

5. This transaction was executed in multiple trades at prices ranging from $489.08 to $490.07. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

6. This transaction was executed in multiple trades at prices ranging from $490.08 to $491.045. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

7. This transaction was executed in multiple trades at prices ranging from $491.10 to $492.07. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

8. This transaction was executed in multiple trades at prices ranging from $492.12 to $492.87. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

9. This transaction was executed in multiple trades at prices ranging from $493.23 to $493.91. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

10. This transaction was executed in multiple trades at prices ranging from $494.28 to $495.01. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

11. This transaction was executed in multiple trades at prices ranging from $495.39 to $496.26. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

12. Shares held in family trusts as to which the Reporting Person shares investment power and the Reporting Person and/or immediate family members are beneficiaries.

13. Shares held in family trusts as to which the Reporting Person's spouse is sole trustee and sole beneficiary or co-trustee and settlor with power to revoke.

14. Shares held in family trusts as to which the Reporting Person's spouse shares investment power and the Reporting Person and/or immediate family members are beneficiaries.

15. Shares held in family trusts as to which the Reporting Person is sole trustee and sole beneficiary or co-trustee and settlor with power to revoke.

Remarks:

	/s/ John S. Hess, Jr. under Power of Attorney	03/05/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did United Therapeutics (UTHR) report for Martine Rothblatt?

United Therapeutics reported that CEO Martine A. Rothblatt exercised 9,500 stock options and sold 19,000 shares of Common Stock on March 4, 2026. These transactions were executed under a pre‑arranged Rule 10b5‑1 trading plan adopted in November 2025.

How many United Therapeutics (UTHR) shares did the CEO sell and at what prices?

The CEO reported open‑market sales totaling 19,000 shares of Common Stock on March 4, 2026. Reported sale prices per share include $486.4229 and go up to $497.0500, with several transactions executed in multiple trades at weighted average prices within disclosed ranges.

What stock options did the United Therapeutics (UTHR) CEO exercise in this Form 4?

Martine A. Rothblatt exercised 9,500 Stock Options on March 4, 2026 at a reported exercise price of $0.0000 per share. Following this transaction, she directly held 211,500 stock options, according to the beneficial ownership figures disclosed in the filing.

How many United Therapeutics (UTHR) shares does the CEO hold after these transactions?

After the reported sales, the CEO directly held 130 shares of Common Stock. Indirect holdings include 166 shares held by spouse and family trust positions of 324,518, 258,117, 45,596, and 10,962 Common Stock shares, as disclosed in the ownership tables.

What is the 10b5-1 trading plan mentioned in the United Therapeutics (UTHR) Form 4?

The filing states that the stock option exercise and sale of resulting common shares were made under a pre‑arranged Rule 10b5‑1 trading plan adopted on November 7, 2025. The plan continues until the earlier of exercising 1,734,410 options or December 31, 2026.

What future transactions does the CEO’s United Therapeutics (UTHR) 10b5-1 plan allow?

According to the footnote, the 10b5‑1 plan will continue until the earlier of the exercise of 1,734,410 stock options, all expiring on March 17, 2027, or December 31, 2026. This framework permits additional option exercises and related share sales within those limits.